Detroit, Michigan, United States
My research interests are in the application of molecular biology, molecular cytogenetics and cancer genomics approaches to understand the genetic basis of cancer. My current research interests are centered on the discovery and characterization of gene fusions in solid cancer and understand their role in cancer development from a translational research perspective. I have been using genomic technologies such as aCGH, FISH, SKY, gene expression microarrays, and next-generation sequencing (NGS) to interrogate the genomic and transcriptome architecture of cancer genome. At Michigan Center for Translational Pathology we pioneered the application of next generation sequencing technology for transcriptome sequencing and discovered recurrent RAF gene fusions in non ETS prostate cancer and identification of cancer specific pseudogenes. Emerging evidence show that cancer can be classified based on molecular aberrations rather than morphological and histological classification. I would like to pursue my future research in this direction using the next-generation sequencing technology to understand the genetic basis of rare cancer types.
https://www.henryford.com/physician-directory/p/palanisamy-nallasivam?tabId=null
Cancer Genomics, Molecular Pathology
I have been using genomic technologies such as aCGH, FISH, SKY, gene expression microarrays, and next-generation sequencing (NGS) to interrogate the transcriptional and genomic architecture of solid cancer genome. At the DNA level, in-depth analyses using high resolution technologies to study copy number changes, particularly genomic amplifications and deletions, have identified rare gene fusions formed at the boundaries of copy number changes. At Michigan Center for Translational Pathology (MCTP), we pioneered the application of next generation sequencing technology for transcriptome sequencing and discovered new recurrent gene fusions in cancer. The primary goal of this approach is to identify novel gene fusions specific for each cancer type. The discovery of recurrent gene RAF gene fusions in non ETS prostate cancer was made possible by these novel computational approaches.